De Novo Antibody Sequencing Without a Reference Genome: A Practical Guide

Reference-Free De Novo Antibody Sequencing: Scope and Use Cases

Reference-free de novo antibody sequencing refers to antibody sequence reconstruction without depending on a known genome, transcript, hybridoma-derived cDNA, or pre-existing antibody sequence. The sequence is inferred from the protein sample by LC-MS/MS, then assembled into heavy and light chain models using peptide overlaps, immunoglobulin domain logic, and expert review.

This approach is useful because antibodies often remain valuable after their biological source is no longer available. A research group may still have a purified monoclonal antibody vial, a legacy ascites-derived antibody, a hybridoma supernatant, or a commercial reagent that performs well in an assay, but the original clone record, hybridoma line, or nucleic acid material may be missing.

In these projects, the practical question is not whether a genome exists somewhere in principle. The question is whether there is a usable genetic template that can recover the antibody sequence. If the answer is no, protein-based de novo sequencing becomes the most direct route.

Reference-free sequencing is especially relevant for antibody rescue, recombinant antibody reproduction, reagent validation, intellectual property documentation, and engineering projects where the antibody binding function is known but the sequence is not.

Why De Novo Antibody Sequencing Is Needed Without a Genetic Reference

The most common trigger is sequence loss. Many useful antibodies were generated before routine sequencing became part of antibody development. Others were obtained from third parties, older hybridoma banks, or discontinued commercial products where the full sequence is not accessible.

Lost hybridoma cell lines are a classic use case. If a hybridoma is no longer viable, PCR and RNA-based sequencing may not be possible, but remaining purified antibody or antibody-rich supernatant can still be analyzed. The resulting sequence can support recombinant expression and long-term preservation of the antibody.

Legacy or proprietary antibodies create a different problem. The antibody may be functionally validated, but the sequence may be unavailable. De novo sequencing can help convert a reagent from a biological black box into a defined molecular tool.

For non-model species or engineered antibodies, database dependence can be risky. A generic immunoglobulin database may help interpret conserved framework or constant regions, but it cannot replace direct peptide evidence in mutated, synthetic, or unusual variable regions.

LC-MS/MS Workflow for De Novo Antibody Sequencing

LC-MS/MS de novo antibody sequencing is designed around redundancy. A single digest usually cannot provide enough evidence to reconstruct an antibody with confidence, especially across CDRs and junctional regions. Multiple digestion and fragmentation strategies create overlapping peptide evidence that can be assembled into chain sequences.

The workflow usually begins with antibody preparation. The sample may be reduced and alkylated to separate heavy and light chains and stabilize cysteine-containing peptides. Depending on the project, chain separation, antibody enrichment, or purity assessment may be performed before digestion.

Multi-enzyme digestion is central to sequence reconstruction. Proteases with different cleavage specificities generate different peptide sets. When peptides from separate digests overlap, they help bridge sequence gaps and reduce the risk that a single missing cleavage site or poorly ionizing peptide blocks assembly.

High-resolution LC-MS/MS then measures peptide precursor masses and fragment ion spectra. De novo sequencing software proposes peptide sequences from the spectra, while immunoglobulin-aware interpretation helps organize those peptides into heavy chain, light chain, framework, CDR, and constant-region context.

1. Antibody enrichment or purity assessment when needed.
2. Reduction, alkylation, and chain handling.
3. Multiple enzymatic digests to improve peptide overlap.
4. LC-MS/MS data acquisition with high-resolution fragmentation.
5. De novo peptide interpretation and sequence tag generation.
6. Heavy and light chain assembly from overlapping peptides.
7. CDR annotation, ambiguity review, and confidence reporting.
8. Intact mass or subunit mass cross-checks when suitable.

Research workflows have shown that combining complementary enzymatic digests, de novo interpretation, and manual validation can support high-confidence monoclonal antibody sequencing (Peng et al., 2021). Newer end-to-end computational workflows continue to improve automation, but the quality of the final sequence still depends on the sample, spectra, coverage, and review process (Xiong et al., 2026).

Recoverable Sequence Information from Protein-Only Samples

Protein-only samples can provide more than isolated peptide matches. A well-designed de novo antibody sequencing project aims to reconstruct meaningful antibody regions and explain the evidence supporting each region.

For many projects, the most valuable deliverable is the mature VH and VL sequence with CDR annotation. These regions enable recombinant expression, antibody engineering, humanization planning, and comparison against future lots or variants.

Constant-region information can also be useful. It helps confirm subclass, chain identity, and whether the protein sample matches the expected format. However, variable regions usually carry the greatest value when the goal is antibody recovery or reproduction.

For projects focused on binding-site definition, antibody CDR sequencing may be the core objective. For projects requiring recombinant recovery, heavy and light chain variable region sequencing is usually more appropriate.

Evidence Standards for Heavy and Light Chain Assignment

Reliable de novo antibody sequencing is not only about generating a sequence. It is about showing why that sequence is trustworthy enough for the intended use. A strong report should describe the peptide evidence, unresolved positions, and chain assignment logic.

Peptide coverage is the first evidence layer. High overall coverage is useful, but local coverage matters more than a single percentage. Missing evidence in a CDR region is more consequential than a missing peptide in a redundant constant-region segment.

Peptide overlap is also important. A peptide sequence supported only by one spectrum may be plausible, but overlap from another digest gives stronger evidence. Overlap is especially valuable across junctions, CDRs, and regions with unusual residues.

Manual spectral review remains important for difficult regions. Automated tools can propose sequence candidates, but expert review helps evaluate ambiguous ion series, competing peptide explanations, unexpected modifications, and residue calls that affect CDR or framework interpretation.

For antibody recovery projects, the report should clearly distinguish confirmed sequence, high-confidence inferred sequence, and unresolved ambiguity. This is more useful than a polished sequence that hides uncertainty.

Technical Challenges in Reference-Free Antibody Sequencing

The best-known limitation is Leu/Ile ambiguity. Leucine and isoleucine have the same mass, so standard LC-MS/MS generally cannot distinguish them directly. Unless additional evidence supports a specific call, these positions should be reported as L/I ambiguity.

Mass coincidence is another challenge. Different amino acid combinations can sometimes generate similar mass differences, especially in short tags or lower-quality spectra. Missing fragment ions can also leave multiple plausible local sequence explanations. These risks are reduced by high-resolution data, overlapping peptides, complementary fragmentation, and manual review.

CDR-H3 is often the most difficult region in monoclonal antibody sequencing. It is highly diverse, produced by V(D)J junctional processes, and may not be well represented by database assumptions. Strong peptide evidence across CDR-H3 is therefore critical.

Sample mixture is a practical challenge. A purified monoclonal antibody is easier to reconstruct than hybridoma supernatant, ascites, serum-containing material, polyclonal antibody, or a sample containing host proteins and stabilizers. In mixed samples, peptides from different antibodies may overlap and chain pairing becomes more complex.

PTMs and processing variants also need careful handling. N-terminal pyroglutamate, C-terminal lysine clipping, deamidation, oxidation, glycosylation, and partial degradation can all appear in antibody MS data. These findings may be important, but they should not be confused with the primary amino acid sequence unless the evidence supports that interpretation.

LC-MS/MS, PCR, and NGS: Choosing the Right Antibody Sequencing Route

LC-MS/MS, PCR, and NGS are not interchangeable. They answer related but different questions and require different starting material.

LC-MS/MS is the best starting point when the antibody protein is the only reliable material. This is common in rescue projects, discontinued antibodies, lost hybridomas, and reagent validation.

PCR or NGS is more appropriate when viable cells or high-quality RNA are available. These methods can recover coding sequences directly and can resolve Leu/Ile positions through codons. However, nucleic acid methods do not prove which protein species is present in the antibody vial.

Orthogonal confirmation is often useful. If both protein and nucleic acid materials exist, combining sequence routes can strengthen confidence. DNA or RNA sequencing can provide coding information, while LC-MS/MS confirms the mature antibody product, PTMs, truncations, and expressed-chain evidence.

Sample Requirements for De Novo Antibody Sequencing

The strongest input is a purified monoclonal antibody with documented concentration, buffer composition, and known subclass or species information. The sample does not need a genome, but it does need enough quality and metadata to support digestion, LC-MS/MS, and interpretation.

• Antibody format: full IgG, Fab, scFv, bispecific, recombinant fragment, or other engineered format.
• Species and subclass if known: human IgG1, mouse IgG2a, rabbit monoclonal, chimeric, humanized, or unknown.
• Available amount, concentration, and storage condition.
• Buffer composition, salts, detergents, preservatives, carrier proteins, glycerol, and stabilizers.
• Purity estimate from SDS-PAGE, SEC, capillary electrophoresis, or supplier documentation.
• Target antigen and any known binding or functional information.
• Project goal: CDR recovery, VH/VL sequence, full chain reconstruction, PTM characterization, or recombinant recovery.

Purified monoclonal antibodies usually provide the clearest path to sequence reconstruction. Lower-purity samples can still be considered, but they may require enrichment and extra QC before sequencing.

Hybridoma supernatants and crude antibody samples require additional caution. Serum proteins, host cell proteins, albumin, gelatin, or mixed immunoglobulins can consume MS/MS sampling depth and complicate chain assembly. For these cases, antibody enrichment and purity checks should be included in project planning.

Metadata improves interpretation. Even simple information such as species, subclass, expected molecular format, antigen target, or purification method can help distinguish plausible chain assignments from background peptides.

De Novo Antibody Sequencing Deliverables and Report Interpretation

A useful de novo antibody sequencing report should make the final sequence traceable to its supporting evidence. The deliverable should not be only a FASTA file or a polished sequence table.

• Heavy chain and light chain amino acid sequences.
• Variable region and constant region annotation.
• CDR1, CDR2, and CDR3 annotation.
• Peptide coverage maps for each chain.
• Ambiguous residue notes, including L/I positions.
• PTM or processing observations when supported by evidence.
• Confidence notes for difficult regions.
• Supporting MS/MS spectra or evidence summaries.

Coverage maps are especially useful because they show where the sequence is directly supported. A high-confidence report should make clear which residues are backed by multiple peptides, which regions rely on limited spectra, and which positions remain unresolved.

Ambiguity notes are not a weakness when they are transparent. For reference-free sequencing, clearly marking uncertain positions is better than presenting unsupported certainty. This is particularly important when the sequence will be used for recombinant expression, antibody engineering, or downstream comparability.

For recombinant antibody recovery, the key output is usually the mature heavy and light chain sequence, especially VH and VL regions. The report should help the project team decide whether the recovered sequence is ready for gene synthesis, expression, and functional validation.

Creative Proteomics Support for Reference-Free Antibody Sequencing

Creative Proteomics supports reference-free antibody sequencing projects by combining antibody sample preparation, multi-enzyme LC-MS/MS, de novo peptide interpretation, heavy/light chain reconstruction, CDR annotation, and evidence review. The workflow is designed for projects where the antibody protein is available but the genome, transcript, hybridoma line, or original sequence record is missing.

Depending on the project goal, the analysis can focus on antibody sequencing service planning, de novo antibody sequencing, LC-MS/MS-based antibody sequencing, CDR recovery, variable region reconstruction, or full-chain sequence evidence.

For teams preserving valuable antibody reagents, a protein-first sequencing workflow can help convert an undocumented antibody into a sequence-defined reagent for recombinant production, validation, engineering, and long-term project continuity.

FAQs

1) Can an antibody be sequenced without a reference genome?

Yes. LC-MS/MS de novo antibody sequencing can reconstruct antibody amino acid sequences from purified protein without using a reference genome, hybridoma, DNA, or RNA. The sequence is inferred from overlapping peptide spectra rather than genomic alignment.

2) Is a hybridoma cell line required for de novo antibody sequencing?

No. Hybridoma cells are useful for PCR or RNA-based sequencing, but they are not required for protein-based de novo sequencing. If purified antibody is available, LC-MS/MS can often recover heavy and light chain sequence information.

3) What sample type is best for LC-MS/MS antibody sequencing?

A purified monoclonal antibody is the best starting material because it reduces peptide mixture complexity. Hybridoma supernatant, ascites, or formulated antibody may require enrichment and quality assessment before sequencing.

4) Can de novo sequencing recover both heavy and light chains?

Yes. De novo antibody sequencing is designed to reconstruct both heavy and light chain sequences when sufficient peptide evidence is present. Chain-specific preparation, overlapping peptides, and constant-region context help support heavy/light assignment.

5) Can LC-MS/MS identify antibody CDR regions?

Yes. LC-MS/MS can provide peptide evidence across CDR regions, including CDR-H3, but confidence depends on coverage and fragmentation quality. CDR-H3 often requires the most careful review because it is highly diverse.

6) What are the main limitations of reference-free antibody sequencing?

The main limitations are incomplete peptide coverage, Leu/Ile ambiguity, PTMs, low-quality spectra, and sample mixtures. A reliable report should mark ambiguous positions rather than overstate sequence certainty.

7) Can de novo antibody sequencing distinguish leucine and isoleucine?

Standard MS/MS usually cannot distinguish leucine and isoleucine because they are isobaric. These positions should be reported as L/I ambiguous unless additional evidence supports a specific residue call.

8) How is de novo antibody sequencing different from peptide mapping?

Peptide mapping confirms an expected sequence by matching peptides to a known reference. De novo antibody sequencing reconstructs the sequence when no reliable reference sequence exists.

9) When should PCR or NGS be used instead?

PCR or NGS should be considered when viable hybridoma cells, B cells, or high-quality RNA are available. These methods can recover coding sequences directly, while LC-MS/MS is preferred when only antibody protein remains.

10) What should an antibody sequencing report include?

A useful report should include heavy and light chain sequences, peptide coverage, CDR annotations, ambiguous positions, detected PTMs, confidence notes, and supporting spectra or coverage maps. It should make clear which regions are directly supported by MS/MS evidence.

Before starting a reference-free antibody sequencing project, define whether the priority is CDR recovery, recombinant expression, full chain reconstruction, or protein-level characterization. That decision determines the digestion strategy, evidence threshold, and final report format.

For Research Use Only. Not for use in diagnostic procedures.

References

1. Peng, W.; Pronker, M. F.; Snijder, J. (2021). Mass Spectrometry-Based De Novo Sequencing of Monoclonal Antibodies Using Multiple Proteases and a Dual Fragmentation Scheme. Journal of Proteome Research, 20, 3559-3566.
2. Cheng, J.; Wang, L.; Rive, C. M.; Holt, R. A.; Morin, G. B.; Chen, D. D. Y. (2020). Complementary Methods for de Novo Monoclonal Antibody Sequencing to Achieve Complete Sequence Coverage. Journal of Proteome Research, 19, 2700-2707.
3. Xiong, Y.; et al. (2026). XA-Novo: high-throughput mass spectrometry-based de novo sequencing technology for monoclonal antibodies and antibody mixtures. Nature Communications, 17, 3391.
4. Le Bihan, T.; et al. (2024). De novo protein sequencing of antibodies for identification of neutralizing antibodies in human plasma post SARS-CoV-2 vaccination. Nature Communications, 15, 8790.
5. de Graaf, S. C.; Hoek, M.; Tamara, S.; Heck, A. J. R. (2022). A perspective toward mass spectrometry-based de novo sequencing of endogenous antibodies. mAbs, 14, 2079449.

For research use only, not intended for any clinical use.